Eli Lilly announced positive Phase 3 trial results for Foundayo in treating obstructive sleep apnea, showing significant reduction in breathing interruptions. This successful trial paves the way for FDA submission by late 2026, potentially opening a new, large market for the company.
Eli Lilly reported that its drug Foundayo met its primary endpoint in a Phase 3 clinical trial for obstructive sleep apnea (OSA) in adults with obesity or who are overweight. The drug demonstrated a significant reduction in breathing interruptions, both in patients using and not using PAP therapy, with a consistent safety profile. This is a major positive development for Eli Lilly as it positions them to enter a large and underserved market, potentially disrupting the current treatment landscape dominated by medical devices. For device manufacturers like ResMed (RMD) and Philips (PHG), this represents a long-term competitive threat, as a pharmaceutical solution could reduce reliance on their PAP machines. Short-term, LLY shares could see a positive reaction, while device makers might face some pressure. The key opportunity for traders is to consider LLY's expanded market potential and the potential long-term headwinds for OSA device companies.